Anti-VEGF therapy
Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study
... regimen, anti-VEGF treatment pro- vides a decrease of CRT on OCT and substantial and stable improvement of visual ...of anti-VEGF therapy with regard to VRI ...
8
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
... monthly anti-VEGF therapy as an indicator of “refractory neovascular AMD” based on abundant clinical experience in practice and scientific summary from clinical ...monthly anti-VEGF ...
11
Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
... Exclusion criteria included: all causes of the hemorrhage other than AMD (such as myopia of more than 6 D); eyes with subfoveal scar; any previous treatment of nAMD (except for nutritional agents); and combination ...
5
Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion
... Fifty-seven eyes of 57 patients (31 men and 26 women) with treatment-naïve acute ME of 1- to 4-months duration secondary to central RVO (CRVO, 15 eyes) or BRVO (42 eyes) were studied. All of the patients who had intra- ...
9
A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
... between VEGFA -2578C/A and VA changes in response to anti-VEGF therapy. Similar to our study, VEGFA-2578 C carriers were more likely to be non-responders based on VA. Although our results would ...
7
Tumor refractoriness to anti-VEGF therapy
... to VEGF blockade ...in anti-VEGF therapy ...with anti-PDGF-B/PDGFBR-β reducing pericyte coverage increases the success of anti-VEGF treatment in the mouse RIP1-TAG2 model ...
10
Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy – a systematic approach to identify and characterize data sources
... Around half of the analyzed data sources (56% [34/64]) recorded data on clinical outcomes (best-corrected visual acuity [BCVA]), most of which also reported the method of BCVA assessment (79% [27/34]). All of the data ...
12
Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer
... with anti- VEGF therapy, OS was improved by first-line anti-EGFR therapy in both KRAS wild-type and RAS wild-type patients, suggesting that anti-EGFR monoclonal antibodies may be ...
7
Pazopanib and anti-VEGF therapy
... randomized to receive 800 mg/d of pazopanib (n = 290) or placebo (n = 145). Patients were either treatment-naïve or had received one prior cytokine-based therapy. The primary endpoint was progression-free survival ...
6
Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy
... tion by inducing Dll4 expression in endothelial cells. Dll4 is the ligand of Notch receptors. Notch signaling pathways play critical roles in cell fate determination and differentia- tion. Dll4 gene expression was found ...
10
Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration
... of anti- vascular endothelial growth factor (VEGF) are the standard treatment for wet ...encoding VEGF pathway members contribute to therapy ...with anti- VEGF was genotyped for ...
8
Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy
... Our study is limited by its size; with only ten patients, strong conclusions are difficult to establish. In addition, the failure of a positive response in one of our primary outcomes, MP, is another limitation. Given ...
8
Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term
... releasing VEGF. Repressing VEGF contributes to new vessel regression in the iris and ...to anti-VEGF therapy, PRP radically improves retinal ischemia and thereby inhibits VEGF ...
8
Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections
... one anti-VEGF injections in the study eye (ranibizumab ...intravitreal anti-VEGF injection in the study ...intravitreal anti-VEGF therapy before the preinjection UWFA, ...
8
Anti EGFL7 antibodies enhance stress induced endothelial cell death and anti VEGF efficacy
... of VEGF blockade. Because anti-VEGF therapy is used to treat multiple, diverse types of cancer in the clinic, we uti- lized a variety of preclinical tumor models to test this ...by ...
14
Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
... previous anti-VEGF therapy (Figure 1A, D, and E), and it may be possible to start the maintenance phase using the PRN regimen to test for dependence in all the converted ...
8
Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to traumatic choroidal rupture
... To our knowledge, only single case reports have been published so far on intravitreal anti-VEGF therapy for traumatic CNV in the past [12–14]. In these cases one in- jection of either ranibizumab ...
6
<p>Issues with Intravitreal Administration of Anti-VEGF Drugs</p>
... to anti-VEGF therapy is a risk factor for a reduction in out fl ow facility and if patients with ocular hypertension were more likely to experience a substantial reduction in out fl ow facility from ...
8
Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series
... combined anti-VEGF and DEX implant in eyes with ME due to ...to anti-VEGF therapy allows the number of anti-VEGF treat- ments to be reduced, while providing efficacy ...
8
Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice
... In this study, we estimated the proportion of patients treated for ocular pathologies with anti-VEGF therapy and needing bilateral injections over a 1-month period. Our data show that the rate of ...
6